Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Recent pharmacological advances for treating venous thromboembolism: are we witnessing the demise of warfarin?

Kumar S, Howell J, Mattock C.

J R Soc Med. 2013 Nov;106(11):441-6. doi: 10.1177/0141076813498232. Epub 2013 Sep 11. Review.

2.

Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.

Liem TK, Deloughery TG.

Semin Vasc Surg. 2011 Sep;24(3):157-61. doi: 10.1053/j.semvascsurg.2011.11.003. Review.

PMID:
22153026
3.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Scaglione F.

Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. Review.

PMID:
23292752
4.

New anticoagulants for the treatment of venous thromboembolism.

Prandoni P, Dalla Valle F, Piovella C, Tormene D, Pesavento R.

Minerva Med. 2013 Apr;104(2):131-39. Review.

PMID:
23514989
5.

Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?

Arepally GM, Ortel TL.

Annu Rev Med. 2015;66:241-53. doi: 10.1146/annurev-med-051113-024633. Review.

PMID:
25587651
6.

Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Fanola CL.

Vasc Health Risk Manag. 2015 May 27;11:271-82. doi: 10.2147/VHRM.S62595. eCollection 2015. Review.

7.

Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.

Saraf K, Morris PD, Garg P, Sheridan P, Storey R.

Postgrad Med J. 2014 Sep;90(1067):520-8. doi: 10.1136/postgradmedj-2014-132605. Epub 2014 Aug 1. Review. Erratum in: Postgrad Med J. 2014 Oct;90(1068):575. Morris, Paul [corrected to Morris, Paul D].

PMID:
25085900
8.

Factor Xa and thrombin as targets for new oral anticoagulants.

Weitz JI.

Thromb Res. 2011 Jan;127 Suppl 2:S5-S12. doi: 10.1016/S0049-3848(10)70147-X.

PMID:
21193114
9.

Advances in the management of venous thromboembolism.

Schulman S.

Best Pract Res Clin Haematol. 2012 Sep;25(3):361-77. doi: 10.1016/j.beha.2012.06.003. Epub 2012 Aug 2. Review.

PMID:
22959552
10.

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.

Salazar CA, Malaga G, Malasquez G.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005981. doi: 10.1002/14651858.CD005981.pub2. Review.

PMID:
20393944
11.

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.

Robertson L, Kesteven P, McCaslin JE.

Cochrane Database Syst Rev. 2015 Dec 4;(12):CD010957. doi: 10.1002/14651858.CD010957.pub2. Review.

PMID:
26636644
12.

New anticoagulants: focus on venous thromboembolism.

Gómez-Outes A, Lecumberri R, Pozo C, Rocha E.

Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. Review.

PMID:
19601856
13.

Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.

Khemasuwan D, Suramaethakul N.

Clin Appl Thromb Hemost. 2012 Sep;18(5):476-86. doi: 10.1177/1076029612438957. Epub 2012 Mar 2. Review.

PMID:
22387584
14.

Pros and cons of new oral anticoagulants.

Bauer KA.

Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. doi: 10.1182/asheducation-2013.1.464. Review.

PMID:
24319220
15.

Alternatives to warfarin--the next generation of anticoagulants.

Kanagasabapathy P, Chowdary P, Gatt A.

Cardiovasc Ther. 2011 Dec;29(6):e80-8. doi: 10.1111/j.1755-5922.2010.00197.x. Epub 2010 Jul 9. Review.

PMID:
20626755
16.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
17.

Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.

Bauer KA.

Stroke. 2013 Jun;44(6 Suppl 1):S38-40. doi: 10.1161/STROKEAHA.111.000387. Review. No abstract available.

18.

Will warfarin ever be replaced?

Ruff CT, Braunwald E.

J Cardiovasc Pharmacol Ther. 2010 Sep;15(3):210-9. doi: 10.1177/1074248410366448. Epub 2010 May 18. Review.

PMID:
20484119
19.

Disadvantages of VKA and requirements for novel anticoagulants.

Shameem R, Ansell J.

Best Pract Res Clin Haematol. 2013 Jun;26(2):103-14. doi: 10.1016/j.beha.2013.07.009. Epub 2013 Jul 23. Review.

PMID:
23953899
20.

[Old and new oral anticoagulants. Pharmacological perspective].

Marques da Silva P.

Rev Port Cardiol. 2012 Apr;31 Suppl 1:6-16. Review. Portuguese.

PMID:
22541030

Supplemental Content

Support Center